- FAX+30 210 6039300
CONSTANT RESEARCH AND DEVELOPMENT FOR THE GOOD OF MANKIND
Elpen the pioneering Greek pharmaceutical company has marked a 50-year course of significant progress. It remains steadily dedicated to excellent quality and to the research of novel therapies.
The vision of its Founder Mr.Dimitrios Pentafragas is served by Elpen, thusly implementing as a primary criterion to its strategic choices and decision, the motto: Caring For Mankind. Within this context, the company has invested well over 7% of its turnover in research programs, while maintaining since 1996 Greece’s largest research center of Applied Biomedical Research, while also being one of the largest such centers in Europe!
Elpen enjoys a significant presence in all the basic therapeutic categories with medicaments of extremely high safety and therapeutic efficacy. The company holds a leading position in the medical sectors of Cardiology and Pneumonology, ranking presently as the 6th pharmaceutical company in the country, among over 400 companies presently active in Greece, both domestic and multinationals.
The development of novel drugs constitutes a primary criterion for Elpen’s strategic choices. It is for this reason that the company constantly invests in state-of-the-art pharmaceutical technology, thus leading the way for novel, high-quality drugs and significant therapeutic value.
A significant ‘fruit’ resulting from this research endeavor is represented by the novel, patented, dry powder inhaler Elpenhaler®, a device conceived and invented by the company’s Founder and Chairman, Mr.Dimitrios Pentafragas, a device which has been approved in 27 European countries with worldwide patent approval in more than 100 countries!
Elpenhaler® is acknowledged as an extremely effective therapeutic weapon in the fight against lung diseases such as asthma and COPD. The quality of its robust construction and its user-friendly functionality certify to its durability during the extensive clinical trials it has undergone up until today.
The development of the novel dry powder inhaler Elpenhaler® led to a significant, pioneering, worldwide decision in favor of Elpen- it is the first pharmaceutical company to have ever received European marketing approval of a generic fixed-dose combination inhaler. The sector of inhaled drugs ranks among the most difficult to receive approval, with drug administration is attained by means of the Elpenhaler® dry powder inhaler device.
Elpen attributes a significant importance to extroversion thus, constantly reinforcing exports activities of pharmaceuticals bearing its brand name. With exports of 30 pharmaceutical products in 27 European countries and 60 countries worldwide, it already constitutes a recognizable presence in Europe, Asia, and Africa. Furthermore, there are future ambitious plans underway with the objective to expand its powerful presence in the world markets.
Since 2012, Elpen has established a subsidiary in Germany, Elpen Pharma GmbH, a company which has already won the respect and trust of German doctors. The manufacturing know-how and the high quality of Elpen pharmaceutical products have led to the establishment of long-term business collaborations with international pharmaceutical companies aimed at the manufacturing of products in its state-of the art facilities, and the supply of medical training and promotion services.
Contributing to our fellow man and society at large, are concepts which represent a perennial compass in the progress of Elpen. This has been practically proven over many years by means of the company’s significant activities in a multitude of Corporate Social Responsibility projects. The company recently sponsored the Greek Anticancer Society in the way of offering free nationwide mammograms for women belonging to vulnerable social groups. This project is testament to the sincerity and seriousness with which Elpen regards its Social Responsibility, an act motivated by neither marketing nor business strategies, granted that Elpen is not a manufacturer nor vendor of oncology medicaments.
Elpen, the pioneering Greek pharmaceutical company actively supports the nation’s economy and employment sectors, creating values which contribute to Development. It is characteristic that during the bleak times of crisis and extreme economic insecurity, the Elpen Group of Companies has managed to reinforce its human resources sector by supporting a staff of 900 employees.
Moreover, it has aimed at promoting a people-centric working environment while functioning as a model European company.
[rev_slider alias=”Elpen SA”][/rev_slider]